Simultaneous TransPRK and Corneal Collagen Cross-Linking
Launched by BRUCE ALLAN · Aug 1, 2014
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
Features which distinguish this trial from previous trials of combined photorefractive keratectomy (PRK) and corneal collagen cross-linking (CXL) are: a rapid, pulsed light, CXL protocol; and a treatment programming algorithm for PRK designed to target higher order aberrations only with no compensatory additional laser corneal tissue removal.
Excimer laser treatment will be performed with the Schwind Amaris 750S laser (www.eye-tech-solutions.com). Unique features of this system utilised here include:
* Pre-programmed transepithelial ablation - laser removal of the minimum area of corneal ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with progressive stage II or III keratoconus
- • CDVA \< 0.00 logMAR or subjective problems with spectacle corrected visual quality (ghost images or light scatter symptoms)
- Exclusion Criteria:
- • Active ocular surface disease
- • Minimum corneal thickness \<390µm (leaving 325µm residual stromal thickness after transPTK - in line with minimum thickness recommendations for the study CXL protocol)
- • Vulnerable groups (patients whose capacity for giving informed consent to participate in the trial may be impaired)
About Bruce Allan
Bruce Allan is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, the organization collaborates with leading researchers and institutions to design and implement rigorous clinical trials. Bruce Allan prioritizes adherence to ethical standards and regulatory compliance, ensuring that all studies are conducted with the utmost integrity and transparency. By leveraging state-of-the-art methodologies and fostering a culture of excellence, Bruce Allan aims to contribute significantly to the development of groundbreaking treatments across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Bruce D Allan, MD FRCOphth
Principal Investigator
Moorfields Eye Hospital NHS Foundation Trust
Dan M Gore, FRCOphth
Principal Investigator
Moorfields Eye Hospital NHS Foundation Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials